Get started
Author

А. И. Хасанова

Observed names: A. I. Khasanova, A. Khasanova, A.  I. Khasanova, A.I. Khasanova, A.  I. Khasanova, Alfia I. Khasanova, Alfia Irekovna Khasanova, Alfia Khasanova, Alfiya Khasanova, А. I. Khasanova
Observed institutions: Kazan Federal University, Russian Cancer Research Center NN Blokhin, Ministry of Health of the Russian Federation, Republican Oncological Clinical Dispensary, Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal, Government of the Republic of Tatarstan
ORCID: 0000-0003-4249-5518
Observed ORCID: 0000-0003-4249-5518
OpenAlex ID: A5019258474
FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma
2016 · I. Tsimafeyeu, A. Khasanova, et al. · Clinical & Translational Oncology · 14
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
2025 · K. Laktionov, A. Smolin, et al. · European Journal of Cancer · 12
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia
2021 · Tatiana N. Sokolova, Svetlana N. Aleksakhina, et al. · Journal of Modern Oncology · 8
PDF
Abstract 4069: FGFR2 expression and mutation are rare in papillary renal cell carcinoma.
2013 · Ilya V. Tsimafeyeu, Nigel Wynn, et al. · Cancer Research · 7
Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
2020 · E. V. Borodavina, P. A. Isaev, et al. · Head and neck tumors (HNT) · 6
PDF
Toxicity and efficacy of gemcitabine plus nab-paclitaxel (paclitaxel + albumin) in a Russian patient population: results of a multicenter retrospective study
2019 · I. A. Pokataev, M. A. Lyadova, et al. · Malignant tumours · 4
PDF
FGFR2 expression to predict survival outcome in patients with metastatic papillary renal cell carcinoma.
2016 · Ilya Tsimafeyeu, Alexandra Naumova, et al. · Journal of Clinical Oncology · 4
Unresectable hepatocellular carcinoma: prospects for drug therapy with lenvatinib
2022 · V.  V. Breder, D.  T. Abdurakhmanov, et al. · Malignant tumours · 2
PDF
Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study
2022 · M.   Yu. Fedyanin, L.  Yu. Vladimirova, et al. · Surgery and Oncology · 1
PDF
Toxicity and efficacy of FOLFIRI regimen and aflibercept combination in metastatic colorectal cancer: first results of a Russian multicenter retrospective study
2019 · M. Yu. Fedyanin, L. Yu. Vladimirova, et al. · Malignant tumours · 1
PDF
Aflibercept (Afl) for patients (pts) with metastatic colorectal cancer (mCRC): Clinical predictors of nonhematologic (nonhem) toxicity.
2019 · Liubov Yu Vladimirova, Mikhail Fedyanin, et al. · Journal of Clinical Oncology · 1
Innovative Technologies for the Solution of Environmental Problems in the World Community
2017 · T. K. Usmanova, A. I. Khasanova, et al. · MIR (Modernization Innovation Research) · 1
PDF
P1.280: Prolgolimab With Chemo as 1st Line Therapy for Patients With Advanced nsNSCLC: Extended 36 Months Follow-Up of Phase III Trial DOMAJOR
2026 · F.V. Moiseenko, K.K. Laktionov, et al. · Journal of Thoracic Oncology
OA11.05 Results of a Phase III Trial of Prolgolimab with Chemotherapy as First-Line Therapy for Patients with Advanced Non-Squamous NSCLC: DOMAJOR
2024 · K. Laktionov, A. Smolin, et al. · Journal of Thoracic Oncology
PDF
Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study
2021 · E. I. Kovalenko, E. V. Artamonova, et al. · Meditsinskiy sovet = Medical Council
PDF
Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: Real life experience
2020 · E. Kovalenko, L. Manzyuk, et al. · European Journal of Cancer
P-291 Retrospective comparison efficacy and toxicity FOLFIRI plus aflibercept or bevacizumab in patients with metastatic colorectal cancer: Results of the multicenter observational study
2020 · M. Fedyanin, V. Chubenko, et al. · Annals of Oncology
PDF
Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study
2019 · I. A. Pokataev, M. A. Lyadova, et al. · Meditsinskiy sovet = Medical Council
PDF
Long-term Responders With Metastatic Breast Cancer (mbc) Receiving Eribulin: Real Life Experience
2019 · Ludmila Zhukova, Vera Gorbunova, et al. · The Breast
Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study
2019 · M. Fedyanin, V. Chubenko, et al. · Annals of Oncology
Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer
2019 · M. Yu. Fedyanin, L. Yu. Vladimirova, et al. · Surgery and Oncology
PDF
Long-term responders with metastatic breast cancer (MBC) receiving eribulin: Real life experience.
2018 · Vera Gorbunova, Ludmila Manzyuk, et al. · Journal of Clinical Oncology
Efficacy and Safety of Eribulin in Combination with Trastuzimab in HER2-Positive Metastatic Breast Cancer Patients: Real Life Experience
2017 · Elena Igorevna Kovalenko, Ludmila Manzyuk, et al. · The Breast
Efficacy and safety of eribulin in various subtypes of breast cancer: data from real clinical practice in Russia
2017 · L. V. Manzyuk, E. I. Kovalenko, et al. · Malignant tumours
Brca-ассоциированный рак молочной железы у представительниц татарской национальности на примере клинического случая
2016 · А. И. Хасанова, M. Gordiev, et al. · Поволжский онкологический вестник
Works count: 27
Citation count: 61
H-index: 5
I10-index: 2
Year
Topic
Type